Antiplatelet Therapy for Mild to Moderate Carotid Plaque
For patients with asymptomatic mild to moderate carotid stenosis, low-dose aspirin (75-100 mg daily) should be considered if bleeding risk is low, particularly in those at increased cardiovascular risk (e.g., diabetic patients). 1
Evidence-Based Approach
Asymptomatic Disease (Mild to Moderate Stenosis)
The most recent and authoritative guidance comes from the 2024 ESC Guidelines, which provide a nuanced recommendation:
For asymptomatic carotid stenosis >50%: Long-term antiplatelet therapy (commonly low-dose aspirin) should be considered if bleeding risk is low (Class IIa, Level C) 1
Key consideration: These patients have approximately twice the risk of myocardial infarction compared to the general population, making cardiovascular protection particularly important 1
The 2012 ACCP Guidelines similarly recommend aspirin 75-100 mg daily for asymptomatic carotid stenosis (Grade 2B), noting that aspirin slightly reduces total mortality over 10 years regardless of cardiovascular risk profile 2
Clinical Decision Algorithm
Start antiplatelet therapy if:
- Stenosis ≥50% (even if asymptomatic)
- Additional cardiovascular risk factors present (diabetes, hypertension, hyperlipidemia)
- Low bleeding risk (no history of major bleeding, not on anticoagulation)
- Life expectancy >5 years
Consider withholding if:
- Very low-grade stenosis (<50%)
- High bleeding risk (prior major bleeding, concurrent anticoagulation)
- Patient averse to long-term medication for small absolute benefit
Important Caveats
The evidence quality is limited: The only RCT specifically addressing asymptomatic carotid stenosis (the Asymptomatic Cervical Bruit Study) enrolled only 188 patients per arm and failed to show superiority of aspirin versus placebo 1. However, observational data consistently shows reduced cardiovascular events with antiplatelet therapy.
Dual antiplatelet therapy (DAPT) is NOT indicated for asymptomatic disease—combining aspirin and clopidogrel shows no benefit over single antiplatelet therapy in this population 1
Medical therapy has evolved: Modern optimal medical therapy (statins, blood pressure control, lifestyle modification) has dramatically reduced stroke rates in asymptomatic patients, making the absolute benefit of aspirin smaller than in older trials 1
Symptomatic Disease (Different Scenario)
If the patient has had symptoms (stroke or TIA) related to the carotid stenosis, the recommendation changes dramatically:
- DAPT with aspirin and clopidogrel 75 mg is recommended for the first 21 days or longer (Class I, Level A) 1
- Followed by long-term single antiplatelet therapy (clopidogrel preferred over aspirin) 2
Practical Implementation
Preferred regimen for asymptomatic disease: Aspirin 75-100 mg daily (81 mg is the common US dose)
Duration: Lifelong, as this is for cardiovascular risk reduction, not just stroke prevention
Monitoring: Annual follow-up to assess cardiovascular risk factors, treatment adherence, and bleeding complications 1
The decision ultimately balances the modest reduction in cardiovascular events against the increased bleeding risk, with the scales tipping toward treatment in patients with additional cardiovascular risk factors and low bleeding risk.